SLC5A2 and hydrops fetalis: Recent data also indicated a potential impact of novel drugs used in HF therapy in reducing PAP in patients with PH-LHD, including angiotensin receptor–neprilysin inhibitor (ARNI) and sodium–glucose cotransporter-2 (SGLT-2) inhibitors [97].